Wegovy Pill Shows Superior Weight Loss Over Foundayo
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2026
0mins
Source: CNBC
- Weight Loss Efficacy: The Wegovy pill demonstrated significantly greater mean weight loss of 16.6% compared to Eli Lilly's Foundayo, which showed only 12.4%, indicating Wegovy's competitive edge in the weight-loss drug market.
- Patient Preference Insights: An analysis by Novo revealed that 84% of patients preferred the drug profile of Wegovy, highlighting strong patient recognition of its lifestyle compatibility, which provides robust support for Novo's market promotion efforts.
- Market Competition Dynamics: The launch of the Wegovy pill is seen as the beginning of a new era in weight-loss medications; however, analysts note that the rapid increase in prescriptions may slow down as Foundayo approaches its market entry, potentially impacting Wegovy's market share.
- Side Effect Comparison: Recent studies indicate that Wegovy outperforms Foundayo in terms of discontinuation rates, with the latter associated with about 14 times higher odds of stopping treatment due to side effects, providing Wegovy with a crucial differentiation advantage in the increasingly competitive anti-obesity drug market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 38.520
Low
42.00
Averages
54.67
High
70.00
Current: 38.520
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking Therapeutics' Bullish Outlook with Target Price Raised Significantly
- Target Price Surge: Analysts project Viking Therapeutics' stock to reach $93.59 within the next 12 months, representing a more than 170% increase from its current price, indicating strong market confidence in its weight-loss drug VK2735.
- Clinical Trial Success: VK2735 achieved an average weight loss of up to 14.7% in just 13 weeks, outperforming other market options, with most users able to adhere to the treatment regimen, providing a significant competitive edge in the crowded weight-loss drug market.
- Massive Market Potential: The anti-obesity drug market is expected to grow from $26 billion last year to over $130 billion by 2031, positioning Viking Therapeutics to capture a share of this rapidly expanding market with its unique dual agonist VK2735.
- Analyst Optimism: Despite inherent risks, analysts remain bullish on Viking Therapeutics, anticipating that upcoming Phase 3 trial data will lead to FDA approval by no later than 2029, suggesting a strong buy sentiment among the majority of analysts covering the stock.
See More
Viking Therapeutics Poised for Growth in Weight-Loss Drug Market
- Market Potential: According to Mordor Intelligence, the anti-obesity drug market is projected to grow from $26 billion last year to over $130 billion by 2031, indicating strong growth potential, with Viking Therapeutics well-positioned in this space.
- Clinical Trial Success: Viking Therapeutics' VK2735 achieved an average weight loss of up to 14.7% in just 13 weeks, outperforming other options on the market, showcasing its competitive edge in the weight-loss drug sector and potentially attracting more users.
- Analyst Optimism: Wall Street's consensus price target for Viking Therapeutics stands at $93.59, over 170% above its current price, reflecting analysts' strong optimism regarding upcoming clinical trial data and suggesting potential FDA approval.
- Differentiation Advantage: VK2735, as a dual agonist incorporating both GLP-1 and GIP therapies, offers a competitive edge with its tolerability and efficacy, which may help it stand out in a crowded market despite similarities in underlying mechanisms with other drugs.
See More
Amazon Launches GLP-1 Weight Management Program
- Service Launch: Amazon One Medical has announced a weight management program centered around GLP-1 treatments, aiming to address obesity as a chronic condition by integrating medical services to provide personalized solutions, thereby enhancing the overall healthcare experience for patients.
- Drug Accessibility: The program allows patients to order popular GLP-1 medications, including Foundayo and oral Wegovy, online at prices comparable to the market, while also offering 24/7 prescription renewals, significantly simplifying the weight loss journey for patients.
- Market Potential: With the surging demand for GLP-1 drugs, Amazon's weight management program is poised to attract a large number of patients, potentially driving revenue growth for Amazon One Medical through membership fees and medical services, thereby enhancing its competitiveness in the healthcare sector.
- Strategic Implications: Although Amazon's cloud computing business remains its primary profit driver, the weight management program could emerge as a significant growth engine for its healthcare services, further solidifying Amazon's position in the rapidly expanding GLP-1 market.
See More
Amazon Launches GLP-1 Weight Management Program
- Market Potential: The GLP-1 drug market is projected to approach $100 billion by 2030, with Eli Lilly and Novo Nordisk dominating the space and recently launching oral medications Foundayo and Wegovy, indicating strong market demand and competitive pressure.
- Amazon's Healthcare Strategy: Amazon is leveraging its One Medical platform to launch a GLP-1 weight management program that integrates virtual and in-person medical services, aiming to provide personalized weight loss solutions that cater to patients' needs for convenient healthcare, thereby enhancing its competitiveness in the healthcare sector.
- Convenient Access to Medications: Patients can easily order GLP-1 medications through Amazon One Medical, benefiting from fast delivery services, while existing patients enjoy 24/7 prescription renewals, which may attract more patients to choose Amazon as their preferred weight loss platform.
- Growth Drivers: Amazon's weight management program is expected to drive growth for One Medical through membership fees and medical service revenues; although GLP-1 drugs may not become a major growth engine for Amazon's overall business, they could represent a significant revenue source within its healthcare services ecosystem.
See More
Lilly and Novo Nordisk Compete in Oral Obesity Drug Market
- Market Performance Comparison: Lilly's oral obesity drug Foundayo garnered 3,707 prescriptions in its second week, significantly lower than Novo Nordisk's Wegovy, which achieved 18,410 prescriptions in the same period, indicating a weaker market acceptance for Lilly that could impact future sales performance.
- Prescription Growth Discrepancy: Foundayo only received 1,390 prescriptions in its debut week, while Wegovy reached 3,071 prescriptions in its first four days, highlighting Novo's clear advantage in market promotion and consumer acceptance, potentially leading to a loss of market share for Lilly.
- FDA Approval and Market Outlook: Foundayo was approved by the FDA earlier this month for use alongside a reduced-calorie diet and increased physical activity; however, despite showing significant weight loss in clinical trials, the market response has not met expectations, which may affect the company's long-term strategy.
- Investor Sentiment Shift: Although Lilly's stock fell 4% on Friday, retail sentiment on Stocktwits shifted from 'neutral' to 'bullish', indicating market expectations for future potential, which may provide support for the company's subsequent performance.
See More
Eli Lilly's Foundayo Faces Sales Challenges Post FDA Approval
- Initial Prescription Struggles: Eli Lilly's Foundayo received only 1,390 prescriptions in its first week post-FDA approval, increasing to 3,707 in the second week, yet this pales in comparison to Novo Nordisk's Wegovy, which garnered 18,410 prescriptions, indicating a concerning market reception that could impact future sales expectations.
- Stock Price Decline Reflects Concerns: The disappointing initial sales performance led to a nearly 4% drop in Eli Lilly's stock price on Friday, reflecting investor skepticism about the new product's viability, which may result in short-term capital outflows and affect the company's market capitalization.
- Intensifying Market Competition: As Eli Lilly's first FDA-approved weight-loss pill, Foundayo faces formidable competition from Wegovy, which has already established a strong reputation and sales record, complicating Foundayo's market outlook and necessitating close monitoring of its subsequent performance.
- Long-Term Potential Remains: Despite Foundayo's poor initial sales data, Eli Lilly, as a major pharmaceutical company with a diverse product portfolio, has demonstrated potential in the weight-loss category with Zepbound's success, suggesting that investors should focus on long-term growth rather than short-term fluctuations.
See More
Viking Therapeutics' Bullish Outlook with Target Price Raised Significantly
- Target Price Surge: Analysts project Viking Therapeutics' stock to reach $93.59 within the next 12 months, representing a more than 170% increase from its current price, indicating strong market confidence in its weight-loss drug VK2735.
- Clinical Trial Success: VK2735 achieved an average weight loss of up to 14.7% in just 13 weeks, outperforming other market options, with most users able to adhere to the treatment regimen, providing a significant competitive edge in the crowded weight-loss drug market.
- Massive Market Potential: The anti-obesity drug market is expected to grow from $26 billion last year to over $130 billion by 2031, positioning Viking Therapeutics to capture a share of this rapidly expanding market with its unique dual agonist VK2735.
- Analyst Optimism: Despite inherent risks, analysts remain bullish on Viking Therapeutics, anticipating that upcoming Phase 3 trial data will lead to FDA approval by no later than 2029, suggesting a strong buy sentiment among the majority of analysts covering the stock.
See More
Viking Therapeutics Poised for Growth in Weight-Loss Drug Market
- Market Potential: According to Mordor Intelligence, the anti-obesity drug market is projected to grow from $26 billion last year to over $130 billion by 2031, indicating strong growth potential, with Viking Therapeutics well-positioned in this space.
- Clinical Trial Success: Viking Therapeutics' VK2735 achieved an average weight loss of up to 14.7% in just 13 weeks, outperforming other options on the market, showcasing its competitive edge in the weight-loss drug sector and potentially attracting more users.
- Analyst Optimism: Wall Street's consensus price target for Viking Therapeutics stands at $93.59, over 170% above its current price, reflecting analysts' strong optimism regarding upcoming clinical trial data and suggesting potential FDA approval.
- Differentiation Advantage: VK2735, as a dual agonist incorporating both GLP-1 and GIP therapies, offers a competitive edge with its tolerability and efficacy, which may help it stand out in a crowded market despite similarities in underlying mechanisms with other drugs.
See More
Amazon Launches GLP-1 Weight Management Program
- Service Launch: Amazon One Medical has announced a weight management program centered around GLP-1 treatments, aiming to address obesity as a chronic condition by integrating medical services to provide personalized solutions, thereby enhancing the overall healthcare experience for patients.
- Drug Accessibility: The program allows patients to order popular GLP-1 medications, including Foundayo and oral Wegovy, online at prices comparable to the market, while also offering 24/7 prescription renewals, significantly simplifying the weight loss journey for patients.
- Market Potential: With the surging demand for GLP-1 drugs, Amazon's weight management program is poised to attract a large number of patients, potentially driving revenue growth for Amazon One Medical through membership fees and medical services, thereby enhancing its competitiveness in the healthcare sector.
- Strategic Implications: Although Amazon's cloud computing business remains its primary profit driver, the weight management program could emerge as a significant growth engine for its healthcare services, further solidifying Amazon's position in the rapidly expanding GLP-1 market.
See More
Amazon Launches GLP-1 Weight Management Program
- Market Potential: The GLP-1 drug market is projected to approach $100 billion by 2030, with Eli Lilly and Novo Nordisk dominating the space and recently launching oral medications Foundayo and Wegovy, indicating strong market demand and competitive pressure.
- Amazon's Healthcare Strategy: Amazon is leveraging its One Medical platform to launch a GLP-1 weight management program that integrates virtual and in-person medical services, aiming to provide personalized weight loss solutions that cater to patients' needs for convenient healthcare, thereby enhancing its competitiveness in the healthcare sector.
- Convenient Access to Medications: Patients can easily order GLP-1 medications through Amazon One Medical, benefiting from fast delivery services, while existing patients enjoy 24/7 prescription renewals, which may attract more patients to choose Amazon as their preferred weight loss platform.
- Growth Drivers: Amazon's weight management program is expected to drive growth for One Medical through membership fees and medical service revenues; although GLP-1 drugs may not become a major growth engine for Amazon's overall business, they could represent a significant revenue source within its healthcare services ecosystem.
See More
Lilly and Novo Nordisk Compete in Oral Obesity Drug Market
- Market Performance Comparison: Lilly's oral obesity drug Foundayo garnered 3,707 prescriptions in its second week, significantly lower than Novo Nordisk's Wegovy, which achieved 18,410 prescriptions in the same period, indicating a weaker market acceptance for Lilly that could impact future sales performance.
- Prescription Growth Discrepancy: Foundayo only received 1,390 prescriptions in its debut week, while Wegovy reached 3,071 prescriptions in its first four days, highlighting Novo's clear advantage in market promotion and consumer acceptance, potentially leading to a loss of market share for Lilly.
- FDA Approval and Market Outlook: Foundayo was approved by the FDA earlier this month for use alongside a reduced-calorie diet and increased physical activity; however, despite showing significant weight loss in clinical trials, the market response has not met expectations, which may affect the company's long-term strategy.
- Investor Sentiment Shift: Although Lilly's stock fell 4% on Friday, retail sentiment on Stocktwits shifted from 'neutral' to 'bullish', indicating market expectations for future potential, which may provide support for the company's subsequent performance.
See More
Eli Lilly's Foundayo Faces Sales Challenges Post FDA Approval
- Initial Prescription Struggles: Eli Lilly's Foundayo received only 1,390 prescriptions in its first week post-FDA approval, increasing to 3,707 in the second week, yet this pales in comparison to Novo Nordisk's Wegovy, which garnered 18,410 prescriptions, indicating a concerning market reception that could impact future sales expectations.
- Stock Price Decline Reflects Concerns: The disappointing initial sales performance led to a nearly 4% drop in Eli Lilly's stock price on Friday, reflecting investor skepticism about the new product's viability, which may result in short-term capital outflows and affect the company's market capitalization.
- Intensifying Market Competition: As Eli Lilly's first FDA-approved weight-loss pill, Foundayo faces formidable competition from Wegovy, which has already established a strong reputation and sales record, complicating Foundayo's market outlook and necessitating close monitoring of its subsequent performance.
- Long-Term Potential Remains: Despite Foundayo's poor initial sales data, Eli Lilly, as a major pharmaceutical company with a diverse product portfolio, has demonstrated potential in the weight-loss category with Zepbound's success, suggesting that investors should focus on long-term growth rather than short-term fluctuations.
See More
